Journal: BMC cancer

Article Title: Targeting INF2 with DiosMetin 7-O-β-D-Glucuronide: a new stratagem for colorectal cancer therapy.

doi: 10.1186/s12885-025-14357-9

Figure Lengend Snippet: Fig. 2 INF2 was determined to have the most significant impact on the prognosis of CRC patients by machine learning methods: (A) Univariate COX regression analysis for the top 200 signature genes, and select nine genes associated with CRC patient prognosis. B SVM-RFE analysis for the nine candidate genes. C Logistic analysis for the nine candidate genes. D-E LASSO analysis for the nine candidate genes. F Boruta random forest analysis for the nine candidate genes. G-H Decision Tree method analysis for the nine candidate genes. I The expression of INF2 ex-pression in CRC patients with DSS event, poor therapy outcome and perineural invasion from TCGA cohort. J The cell location of INF2. * represents p < 0.05. Data are shown as mean ± SD

Article Snippet: Subsequently, the sections were incubated with an anti-INF2 antibody (1:1000; cat no. 20466–1-AP, Proteintech, Wuhan, China), anti-KI67 (1:4000; cat no. 27309–1-AP, Proteintech), and antiPCNA (1:5000; cat no. 27309–1-AP, Proteintech) overnight at 4 °C.

Techniques: Expressing

Journal: BMC cancer

Article Title: Targeting INF2 with DiosMetin 7-O-β-D-Glucuronide: a new stratagem for colorectal cancer therapy.

doi: 10.1186/s12885-025-14357-9

Figure Lengend Snippet: Fig. 3 INF2 protein was up-regulated in CRC tissues, and positively associated with advanced clinical features and poor outcome: (A-B) IHC stain for INF2 protein in CRC tissues and non-tumor adjacent tissues. C Pairing analysis for INF2 protein between CRC tissues and adjacent non-tumor tissues. D The expression of INF2 protein in the tissues from female and male CRC patients. E The expression of INF2 protein in the tissues from CRC patients aged ≥ 60 or < 60 years. F The expression of INF2 protein in the left and right CRC tissues. G The expression of INF2 protein in CRC tissues provided from patients in N0 stage and N1-N2 stage. H The expression of INF2 protein in CRC tissues provided from patients in I-II stage and III-IV stage. I The survival months of CRC patients with high and low INF2 expression. J The predictive value of INF2 protein for 1-, 3-, and 5-year survival of CRC patients. K The predictive value of INF2 protein for distinguishing adjacent tissues and CRC tissues. L The predictive value of INF2 protein for distinguish high and low tumor grade. ** represents p < 0.01. Data are shown as mean ± SD

Article Snippet: Subsequently, the sections were incubated with an anti-INF2 antibody (1:1000; cat no. 20466–1-AP, Proteintech, Wuhan, China), anti-KI67 (1:4000; cat no. 27309–1-AP, Proteintech), and antiPCNA (1:5000; cat no. 27309–1-AP, Proteintech) overnight at 4 °C.

Techniques: Staining, Expressing

Journal: BMC cancer

Article Title: Targeting INF2 with DiosMetin 7-O-β-D-Glucuronide: a new stratagem for colorectal cancer therapy.

doi: 10.1186/s12885-025-14357-9

Figure Lengend Snippet: Fig. 4 INF2 knockdown inhibited the CRC cell proliferation and mobility in vitro: (A) qRT-PCR detected the effective of siRNAs in inhibiting INF2 mRNA levels. B-C Western blotting detected the effective of siRNAs in inhibiting INF2 protein levels. D CCK-8 assays were used to detect the proliferation rate of INF2-knockdown and NC SW480 and SW620 cells. E–F EDU positive rate was detected in INF2-knockdown and NC SW480 and SW620 cells. G-H Wound healing assay was used to detect the migration ability in INF2-knockdown and NC SW480 and SW620 cells. I-J Wound healing assay was used to detect the invasion ability in INF2-knockdown and NC SW480 and SW620 cells. * represents p < 0.05; ** represents p < 0.01. n = 3. The NC group was used for comparison. Data are shown as mean ± SD

Article Snippet: Subsequently, the sections were incubated with an anti-INF2 antibody (1:1000; cat no. 20466–1-AP, Proteintech, Wuhan, China), anti-KI67 (1:4000; cat no. 27309–1-AP, Proteintech), and antiPCNA (1:5000; cat no. 27309–1-AP, Proteintech) overnight at 4 °C.

Techniques: Knockdown, In Vitro, Quantitative RT-PCR, Western Blot, CCK-8 Assay, Wound Healing Assay, Migration, Comparison

Journal: BMC cancer

Article Title: Targeting INF2 with DiosMetin 7-O-β-D-Glucuronide: a new stratagem for colorectal cancer therapy.

doi: 10.1186/s12885-025-14357-9

Figure Lengend Snippet: Fig. 5 Knockdown of INF2 significantly reduced SW480 cell proliferation in vivo: (A-B) The proliferation rate of tumor tissues derived from NC SW480 and SW480 cells with INF2 knockdown. C The tumor weight of tumor tissues derived from NC SW480 and SW480 cells with INF2 knockdown. D The weight loss of mice harboring NC SW480 and SW480 cells with INF2 knockdown. E–F The expression of INF2, KI67 and PCNA in the tumor tissues derived from NC SW480 and SW480 cells with INF2 knockdown. * represents p < 0.05; ** represents p < 0.01. n = 5. The NC group was used for comparison. Data are shown as mean ± SD

Article Snippet: Subsequently, the sections were incubated with an anti-INF2 antibody (1:1000; cat no. 20466–1-AP, Proteintech, Wuhan, China), anti-KI67 (1:4000; cat no. 27309–1-AP, Proteintech), and antiPCNA (1:5000; cat no. 27309–1-AP, Proteintech) overnight at 4 °C.

Techniques: Knockdown, In Vivo, Derivative Assay, Expressing, Comparison

Journal: BMC cancer

Article Title: Targeting INF2 with DiosMetin 7-O-β-D-Glucuronide: a new stratagem for colorectal cancer therapy.

doi: 10.1186/s12885-025-14357-9

Figure Lengend Snippet: Fig. 6 DiosMetin 7-O-β-D-Glucuronide had high affinity to INF2 protein: (A) The flow chat of computer virtual screening for INF2 protein. B Top5 FDA-approved drugs with highest docking score for INF2 protein. C Top5 natural products with highest docking score for INF2 protein. Docking model between Uridine 5′-diphosphoglucose (D), Alginic acid (E), DiosMetin 7-O-β-D-Glucuronide (F), 2-O-β-D-Glucopyranosyl-L-ascorbic acid (G), and GDP-D-mannose (H). I-J Cellular Thermal Shift Assay was performed to detect the interactions between molecules and INF2 protein. * represents p < 0.05; ** represents p < 0.01. n = 3. The DMSO treatment group was used for comparison. Data are shown as mean ± SD

Article Snippet: Subsequently, the sections were incubated with an anti-INF2 antibody (1:1000; cat no. 20466–1-AP, Proteintech, Wuhan, China), anti-KI67 (1:4000; cat no. 27309–1-AP, Proteintech), and antiPCNA (1:5000; cat no. 27309–1-AP, Proteintech) overnight at 4 °C.

Techniques: Thermal Shift Assay, Comparison

Journal: BMC cancer

Article Title: Targeting INF2 with DiosMetin 7-O-β-D-Glucuronide: a new stratagem for colorectal cancer therapy.

doi: 10.1186/s12885-025-14357-9

Figure Lengend Snippet: Fig. 7 DiosMetin 7-O-β-D-Glucuronide exhibited high inhibitory effects for CRC cells with high INF2 expression: CCK-8 assays were performed to detect the IC50 of DiosMetin 7-O-β-D-Glucuronide for NC SW480 cells (A), NC SW620 cells (B), SW480 with INF2 knockdown cells (C), SW620 with INF2 knockdown cells (D), CMET (E), CSMC (F), and PBMC (G). n = 6. Data are shown as mean ± SD

Article Snippet: Subsequently, the sections were incubated with an anti-INF2 antibody (1:1000; cat no. 20466–1-AP, Proteintech, Wuhan, China), anti-KI67 (1:4000; cat no. 27309–1-AP, Proteintech), and antiPCNA (1:5000; cat no. 27309–1-AP, Proteintech) overnight at 4 °C.

Techniques: Expressing, CCK-8 Assay, Knockdown